 | • レポートコード：GIR-2104Z05597 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、線維筋痛症治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。線維筋痛症治療薬の種類別市場規模（セロトニンノルエピネフリン再取り込み阻害薬、GABAアナログ、その他）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・線維筋痛症治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Eli Lilly、Actavis、Merck Sharp and Dohme、Daiichi Sankyo、Innovative Med Concepts、Meda、Meiji Seika、Switch Biotech、Theravance、Zynerba Pharmaceuticals、Tonix Pharmaceuticals Holding Corp. (TNXP) ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：セロトニンノルエピネフリン再取り込み阻害薬、GABAアナログ、その他 ・用途別分析2016年-2026年：病院、診療所、その他 ・線維筋痛症治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・線維筋痛症治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・線維筋痛症治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・線維筋痛症治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・線維筋痛症治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Fibromyalgia Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Fibromyalgia Drugs size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Fibromyalgia Drugs market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Fibromyalgia Drugs market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Serotonin Norepinephrine Reuptake Inhibitors
GABA Analogs
Other
Market segment by Application, can be divided into
Hospitals
Clinics
Other
Market segment by players, this report covers
Pfizer
Eli Lilly
Actavis
Merck Sharp and Dohme
Daiichi Sankyo
Innovative Med Concepts
Meda
Meiji Seika
Switch Biotech
Theravance
Zynerba Pharmaceuticals
Tonix Pharmaceuticals Holding Corp. (TNXP)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Fibromyalgia Drugs
1.2 Classification of Fibromyalgia Drugs by Type
1.2.1 Overview: Global Fibromyalgia Drugs Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Fibromyalgia Drugs Revenue Market Share by Type in 2020
1.2.3 Serotonin Norepinephrine Reuptake Inhibitors
1.2.4 GABA Analogs
1.2.5 Other
1.3 Global Fibromyalgia Drugs Market by Application
1.3.1 Overview: Global Fibromyalgia Drugs Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Fibromyalgia Drugs Market Size & Forecast
1.5 Global Fibromyalgia Drugs Market Size and Forecast by Region
1.5.1 Global Fibromyalgia Drugs Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Fibromyalgia Drugs Market Size by Region, (2016-2021)
1.5.3 North America Fibromyalgia Drugs Market Size and Prospect (2016-2026)
1.5.4 Europe Fibromyalgia Drugs Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Fibromyalgia Drugs Market Size and Prospect (2016-2026)
1.5.6 South America Fibromyalgia Drugs Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Fibromyalgia Drugs Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Fibromyalgia Drugs Market Drivers
1.6.2 Fibromyalgia Drugs Market Restraints
1.6.3 Fibromyalgia Drugs Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Fibromyalgia Drugs Product and Solutions
2.1.4 Pfizer Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Eli Lilly
2.2.1 Eli Lilly Details
2.2.2 Eli Lilly Major Business
2.2.3 Eli Lilly Fibromyalgia Drugs Product and Solutions
2.2.4 Eli Lilly Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Eli Lilly Recent Developments and Future Plans
2.3 Actavis
2.3.1 Actavis Details
2.3.2 Actavis Major Business
2.3.3 Actavis Fibromyalgia Drugs Product and Solutions
2.3.4 Actavis Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Actavis Recent Developments and Future Plans
2.4 Merck Sharp and Dohme
2.4.1 Merck Sharp and Dohme Details
2.4.2 Merck Sharp and Dohme Major Business
2.4.3 Merck Sharp and Dohme Fibromyalgia Drugs Product and Solutions
2.4.4 Merck Sharp and Dohme Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Merck Sharp and Dohme Recent Developments and Future Plans
2.5 Daiichi Sankyo
2.5.1 Daiichi Sankyo Details
2.5.2 Daiichi Sankyo Major Business
2.5.3 Daiichi Sankyo Fibromyalgia Drugs Product and Solutions
2.5.4 Daiichi Sankyo Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Daiichi Sankyo Recent Developments and Future Plans
2.6 Innovative Med Concepts
2.6.1 Innovative Med Concepts Details
2.6.2 Innovative Med Concepts Major Business
2.6.3 Innovative Med Concepts Fibromyalgia Drugs Product and Solutions
2.6.4 Innovative Med Concepts Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Innovative Med Concepts Recent Developments and Future Plans
2.7 Meda
2.7.1 Meda Details
2.7.2 Meda Major Business
2.7.3 Meda Fibromyalgia Drugs Product and Solutions
2.7.4 Meda Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Meda Recent Developments and Future Plans
2.8 Meiji Seika
2.8.1 Meiji Seika Details
2.8.2 Meiji Seika Major Business
2.8.3 Meiji Seika Fibromyalgia Drugs Product and Solutions
2.8.4 Meiji Seika Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Meiji Seika Recent Developments and Future Plans
2.9 Switch Biotech
2.9.1 Switch Biotech Details
2.9.2 Switch Biotech Major Business
2.9.3 Switch Biotech Fibromyalgia Drugs Product and Solutions
2.9.4 Switch Biotech Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Switch Biotech Recent Developments and Future Plans
2.10 Theravance
2.10.1 Theravance Details
2.10.2 Theravance Major Business
2.10.3 Theravance Fibromyalgia Drugs Product and Solutions
2.10.4 Theravance Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Theravance Recent Developments and Future Plans
2.11 Zynerba Pharmaceuticals
2.11.1 Zynerba Pharmaceuticals Details
2.11.2 Zynerba Pharmaceuticals Major Business
2.11.3 Zynerba Pharmaceuticals Fibromyalgia Drugs Product and Solutions
2.11.4 Zynerba Pharmaceuticals Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Zynerba Pharmaceuticals Recent Developments and Future Plans
2.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
2.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Details
2.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Major Business
2.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Product and Solutions
2.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Fibromyalgia Drugs Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Fibromyalgia Drugs Players Market Share
3.2.2 Top 10 Fibromyalgia Drugs Players Market Share
3.2.3 Market Competition Trend
3.3 Fibromyalgia Drugs Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Fibromyalgia Drugs Revenue and Market Share by Type (2016-2021)
4.2 Global Fibromyalgia Drugs Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Fibromyalgia Drugs Revenue Market Share by Application (2016-2021)
5.2 Fibromyalgia Drugs Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Fibromyalgia Drugs Revenue by Type (2016-2026)
6.2 North America Fibromyalgia Drugs Revenue by Application (2016-2026)
6.3 North America Fibromyalgia Drugs Market Size by Country
6.3.1 North America Fibromyalgia Drugs Revenue by Country (2016-2026)
6.3.2 United States Fibromyalgia Drugs Market Size and Forecast (2016-2026)
6.3.3 Canada Fibromyalgia Drugs Market Size and Forecast (2016-2026)
6.3.4 Mexico Fibromyalgia Drugs Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Fibromyalgia Drugs Revenue by Type (2016-2026)
7.2 Europe Fibromyalgia Drugs Revenue by Application (2016-2026)
7.3 Europe Fibromyalgia Drugs Market Size by Country
7.3.1 Europe Fibromyalgia Drugs Revenue by Country (2016-2026)
7.3.2 Germany Fibromyalgia Drugs Market Size and Forecast (2016-2026)
7.3.3 France Fibromyalgia Drugs Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Fibromyalgia Drugs Market Size and Forecast (2016-2026)
7.3.5 Russia Fibromyalgia Drugs Market Size and Forecast (2016-2026)
7.3.6 Italy Fibromyalgia Drugs Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Fibromyalgia Drugs Revenue by Type (2016-2026)
8.2 Asia-Pacific Fibromyalgia Drugs Revenue by Application (2016-2026)
8.3 Asia-Pacific Fibromyalgia Drugs Market Size by Region
8.3.1 Asia-Pacific Fibromyalgia Drugs Revenue by Region (2016-2026)
8.3.2 China Fibromyalgia Drugs Market Size and Forecast (2016-2026)
8.3.3 Japan Fibromyalgia Drugs Market Size and Forecast (2016-2026)
8.3.4 South Korea Fibromyalgia Drugs Market Size and Forecast (2016-2026)
8.3.5 India Fibromyalgia Drugs Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Fibromyalgia Drugs Market Size and Forecast (2016-2026)
8.3.7 Australia Fibromyalgia Drugs Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Fibromyalgia Drugs Revenue by Type (2016-2026)
9.2 South America Fibromyalgia Drugs Revenue by Application (2016-2026)
9.3 South America Fibromyalgia Drugs Market Size by Country
9.3.1 South America Fibromyalgia Drugs Revenue by Country (2016-2026)
9.3.2 Brazil Fibromyalgia Drugs Market Size and Forecast (2016-2026)
9.3.3 Argentina Fibromyalgia Drugs Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Fibromyalgia Drugs Revenue by Type (2016-2026)
10.2 Middle East & Africa Fibromyalgia Drugs Revenue by Application (2016-2026)
10.3 Middle East & Africa Fibromyalgia Drugs Market Size by Country
10.3.1 Middle East & Africa Fibromyalgia Drugs Revenue by Country (2016-2026)
10.3.2 Turkey Fibromyalgia Drugs Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Fibromyalgia Drugs Market Size and Forecast (2016-2026)
10.3.4 UAE Fibromyalgia Drugs Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Fibromyalgia Drugs Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Fibromyalgia Drugs Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Fibromyalgia Drugs Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Fibromyalgia Drugs Revenue (USD Million) by Region (2016-2021)
Table 5. Global Fibromyalgia Drugs Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Fibromyalgia Drugs Product and Solutions
Table 9. Pfizer Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 11. Eli Lilly Major Business
Table 12. Eli Lilly Fibromyalgia Drugs Product and Solutions
Table 13. Eli Lilly Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Actavis Corporate Information, Head Office, and Major Competitors
Table 15. Actavis Major Business
Table 16. Actavis Fibromyalgia Drugs Product and Solutions
Table 17. Actavis Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Merck Sharp and Dohme Corporate Information, Head Office, and Major Competitors
Table 19. Merck Sharp and Dohme Major Business
Table 20. Merck Sharp and Dohme Fibromyalgia Drugs Product and Solutions
Table 21. Merck Sharp and Dohme Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Daiichi Sankyo Corporate Information, Head Office, and Major Competitors
Table 23. Daiichi Sankyo Major Business
Table 24. Daiichi Sankyo Fibromyalgia Drugs Product and Solutions
Table 25. Daiichi Sankyo Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Innovative Med Concepts Corporate Information, Head Office, and Major Competitors
Table 27. Innovative Med Concepts Major Business
Table 28. Innovative Med Concepts Fibromyalgia Drugs Product and Solutions
Table 29. Innovative Med Concepts Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Meda Corporate Information, Head Office, and Major Competitors
Table 31. Meda Major Business
Table 32. Meda Fibromyalgia Drugs Product and Solutions
Table 33. Meda Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Meiji Seika Corporate Information, Head Office, and Major Competitors
Table 35. Meiji Seika Major Business
Table 36. Meiji Seika Fibromyalgia Drugs Product and Solutions
Table 37. Meiji Seika Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Switch Biotech Corporate Information, Head Office, and Major Competitors
Table 39. Switch Biotech Major Business
Table 40. Switch Biotech Fibromyalgia Drugs Product and Solutions
Table 41. Switch Biotech Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Theravance Corporate Information, Head Office, and Major Competitors
Table 43. Theravance Major Business
Table 44. Theravance Fibromyalgia Drugs Product and Solutions
Table 45. Theravance Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Zynerba Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 47. Zynerba Pharmaceuticals Major Business
Table 48. Zynerba Pharmaceuticals Fibromyalgia Drugs Product and Solutions
Table 49. Zynerba Pharmaceuticals Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Tonix Pharmaceuticals Holding Corp. (TNXP) Corporate Information, Head Office, and Major Competitors
Table 51. Tonix Pharmaceuticals Holding Corp. (TNXP) Major Business
Table 52. Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Product and Solutions
Table 53. Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Fibromyalgia Drugs Revenue (USD Million) by Players (2019-2021)
Table 55. Global Fibromyalgia Drugs Revenue Share by Players (2019-2021)
Table 56. Breakdown of Fibromyalgia Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Fibromyalgia Drugs Players Head Office, Products and Services Provided
Table 58. Fibromyalgia Drugs Mergers & Acquisitions in the Past Five Years
Table 59. Fibromyalgia Drugs New Entrants and Expansion Plans
Table 60. Global Fibromyalgia Drugs Revenue (USD Million) by Type (2016-2021)
Table 61. Global Fibromyalgia Drugs Revenue Share by Type (2016-2021)
Table 62. Global Fibromyalgia Drugs Revenue Forecast by Type (2021-2026)
Table 63. Global Fibromyalgia Drugs Revenue by Application (2016-2021)
Table 64. Global Fibromyalgia Drugs Revenue Forecast by Application (2021-2026)
Table 65. North America Fibromyalgia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Fibromyalgia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Fibromyalgia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Fibromyalgia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Fibromyalgia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Fibromyalgia Drugs Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Fibromyalgia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Fibromyalgia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Fibromyalgia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Fibromyalgia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Fibromyalgia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Fibromyalgia Drugs Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Fibromyalgia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Fibromyalgia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Fibromyalgia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Fibromyalgia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Fibromyalgia Drugs Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Fibromyalgia Drugs Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Fibromyalgia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Fibromyalgia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Fibromyalgia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Fibromyalgia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Fibromyalgia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Fibromyalgia Drugs Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Fibromyalgia Drugs Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Fibromyalgia Drugs Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Fibromyalgia Drugs Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Fibromyalgia Drugs Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Fibromyalgia Drugs Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Fibromyalgia Drugs Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Fibromyalgia Drugs Picture
Figure 2. Global Fibromyalgia Drugs Revenue Market Share by Type in 2020
Figure 3. Serotonin Norepinephrine Reuptake Inhibitors
Figure 4. GABA Analogs
Figure 5. Other
Figure 6. Fibromyalgia Drugs Revenue Market Share by Application in 2020
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Other Picture
Figure 10. Global Fibromyalgia Drugs Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Fibromyalgia Drugs Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Fibromyalgia Drugs Revenue Market Share by Region (2016-2026)
Figure 13. Global Fibromyalgia Drugs Revenue Market Share by Region in 2020
Figure 14. North America Fibromyalgia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Fibromyalgia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Fibromyalgia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Fibromyalgia Drugs Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Fibromyalgia Drugs Market Drivers
Figure 19. Fibromyalgia Drugs Market Restraints
Figure 20. Fibromyalgia Drugs Market Trends
Figure 21. Pfizer Recent Developments and Future Plans
Figure 22. Eli Lilly Recent Developments and Future Plans
Figure 23. Actavis Recent Developments and Future Plans
Figure 24. Merck Sharp and Dohme Recent Developments and Future Plans
Figure 25. Daiichi Sankyo Recent Developments and Future Plans
Figure 26. Innovative Med Concepts Recent Developments and Future Plans
Figure 27. Meda Recent Developments and Future Plans
Figure 28. Meiji Seika Recent Developments and Future Plans
Figure 29. Switch Biotech Recent Developments and Future Plans
Figure 30. Theravance Recent Developments and Future Plans
Figure 31. Zynerba Pharmaceuticals Recent Developments and Future Plans
Figure 32. Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Developments and Future Plans
Figure 34. Global Fibromyalgia Drugs Revenue Share by Players in 2020
Figure 35. Fibromyalgia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 36. Global Top 3 Players Fibromyalgia Drugs Revenue Market Share in 2020
Figure 37. Global Top 10 Players Fibromyalgia Drugs Revenue Market Share in 2020
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 39. Global Fibromyalgia Drugs Revenue Share by Type in 2020
Figure 40. Global Fibromyalgia Drugs Market Share Forecast by Type (2021-2026)
Figure 41. Global Fibromyalgia Drugs Revenue Share by Application in 2020
Figure 42. Global Fibromyalgia Drugs Market Share Forecast by Application (2021-2026)
Figure 43. North America Fibromyalgia Drugs Sales Market Share by Type (2016-2026)
Figure 44. North America Fibromyalgia Drugs Sales Market Share by Application (2016-2026)
Figure 45. North America Fibromyalgia Drugs Revenue Market Share by Country (2016-2026)
Figure 46. United States Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Canada Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Mexico Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Europe Fibromyalgia Drugs Sales Market Share by Type (2016-2026)
Figure 50. Europe Fibromyalgia Drugs Sales Market Share by Application (2016-2026)
Figure 51. Europe Fibromyalgia Drugs Revenue Market Share by Country (2016-2026)
Figure 52. Germany Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. France Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. United Kingdom Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Russia Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Italy Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Asia-Pacific Fibromyalgia Drugs Sales Market Share by Type (2016-2026)
Figure 58. Asia-Pacific Fibromyalgia Drugs Sales Market Share by Application (2016-2026)
Figure 59. Asia-Pacific Fibromyalgia Drugs Revenue Market Share by Region (2016-2026)
Figure 60. China Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Japan Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. South Korea Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. India Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. Southeast Asia Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Australia Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South America Fibromyalgia Drugs Sales Market Share by Type (2016-2026)
Figure 67. South America Fibromyalgia Drugs Sales Market Share by Application (2016-2026)
Figure 68. South America Fibromyalgia Drugs Revenue Market Share by Country (2016-2026)
Figure 69. Brazil Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Argentina Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Middle East and Africa Fibromyalgia Drugs Sales Market Share by Type (2016-2026)
Figure 72. Middle East and Africa Fibromyalgia Drugs Sales Market Share by Application (2016-2026)
Figure 73. Middle East and Africa Fibromyalgia Drugs Revenue Market Share by Country (2016-2026)
Figure 74. Turkey Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Saudi Arabia Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. UAE Fibromyalgia Drugs Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
世界の線維筋痛症治療薬市場規模・現状・予測（2021年-2027年） Fibromyalgia (FM) is a medical condition characterised by chronic widespread pain and a heightened pain response to pressure. The APAC is a major untapped market with many leading vendors in the global fibromyalgia drugs market. Market Analysis and Insights: Global Fibromyalgia Drugs Market The glob…- 世界の線維筋痛症治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Fibromyalgia Therapeutics Market The global Fibromyalgia Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, th…
- 世界の線維筋痛症治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Fibromyalgia Treatment Drug Market The global Fibromyalgia Treatment Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data integrity…
- 世界の神経因性疼痛治療薬市場規模・現状・予測（2021年-2027年） Neuropathic pain is pain caused by damage or disease affecting the somatosensory nervous system. Neuropathic pain may be associated with abnormal sensations called dysesthesia or pain from normally non-painful stimuli (allodynia). In terms of value, North America is a large market and is expected to…
- 世界のイロプロスト薬市場規模・現状・予測（2021年-2027年） Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues. North America is estimated to have a major share in the global market with 75%. Market Analysis…